Resona Asset Management Co. Ltd. Has $28.62 Million Stock Holdings in Elevance Health, Inc. $ELV

Resona Asset Management Co. Ltd. cut its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 88,703 shares of the company’s stock after selling 3,514 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Elevance Health were worth $28,620,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vermillion & White Wealth Management Group LLC increased its holdings in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. bought a new position in shares of Elevance Health in the second quarter valued at approximately $32,000. Glass Jacobson Investment Advisors llc boosted its position in shares of Elevance Health by 400.0% during the second quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after buying an additional 80 shares during the last quarter. Motco raised its position in Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares during the last quarter. Finally, Trust Co. of Toledo NA OH bought a new position in Elevance Health during the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $370.77 on Friday. The firm has a 50-day moving average price of $349.17 and a 200-day moving average price of $328.79. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $82.40 billion, a price-to-earnings ratio of 15.16, a PEG ratio of 1.91 and a beta of 0.51.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $431.00 price objective on shares of Elevance Health in a research report on Tuesday, January 6th. Robert W. Baird boosted their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Weiss Ratings upgraded Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Finally, Truist Financial set a $400.00 price objective on Elevance Health in a research note on Tuesday, October 14th. Twelve equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $399.63.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.